CAPR Falls 13%
Capricor Therapeutics stock is trading lower after the FDA plans to convene an advisory committee meeting to discuss the company's Biologics License Application for Deramiocel
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
CAPR: FDA Plans Advisory Meeting
Capricor Therapeutics' BLA for Deramiocel is set to be discussed by the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee